Navigation Links
Intercell Announces Q4 and Preliminary Full Year 2009 Financial Results
Date:3/2/2010

Global marketing and sales efforts for IXIARO®/JESPECT® by Intercell's partners to increase awareness and vaccination recommendations are the basis for growing product uptake in 2010. According to current plans, product sales are expected to increase as of Q2 2010. Product supplies to marketing and distribution partners for the main travel season are expected to partially shift from Q1 to Q2 2010 due to lot release timing for European markets.

To increase the product's global reach, Intercell has initiated a Phase III study for pediatric label extension of IXIARO®/JESPECT®. In addition, the Company is pursuing further regulatory approvals and continues the product development for endemic countries through its partner, Biological E. Following discussion with regulatory authorities in India, the start of Phase III pediatric trials by Biological E. is now planned by the end of 2010.

TD Vaccine Patch - First-ever patch vaccine in Phase III and basis for patch collaboration with GSK

In December 2009, Intercell signed a key collaboration agreement with GlaxoSmithKline B
'/>"/>

SOURCE Intercell AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
2. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
3. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. Iomai Stockholders Approve Merger With Intercell Subsidiary
6. Iomai, Intercell Chief Scientific Officers to Speak on Future of Vaccines at BIO International Convention Today
7. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
8. Neogen Corporation Announces 3rd Quarter Results Conference Call
9. Raising Awareness of Rare Diseases, Anson Group Announces Sponsorship of Rare Disease Day
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , Inc. ... marketer of proprietary clinical grade hypothermic storage and ... products for cells and tissues  ("BioLife" or the "Company"), ... of Stockholders on May 4, 2015 (the "Annual Meeting"). ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... , , , , ... of purifying amplicons as small as 100bp. AMPure yields high quality PCR , ... or filtration steps. The protocol can be easily automated or performed , ... , EFFICIENT PCR PURIFICATION ...
... , , , , Here are some troubleshooting hints that we have gathered , ... , , , , ... <a , href="#Option4">Primer annealing temperature is too low ... , , ...
... , , , , , , ... PCR primers , that are specific for that mRNA sequence. The ... of cDNA and an amplified , product derived from contaminating genomic ... (see figure below). , , , , , ...
Cached Biology Technology:AMPURE PURIFICATION SYSTEM 2AMPURE PURIFICATION SYSTEM 3Trouble-shooting: Smeared bands 2Trouble-shooting: Smeared bands 3Trouble-shooting: Smeared bands 4Trouble-shooting: Smeared bands 5
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... variety of canary seeds bred specifically for human consumption qualifies ... with celiac disease (CD), scientists have confirmed in a study ... . Joyce Irene Boye and colleagues point out ... alone have CD. They develop gastrointestinal and other symptoms from ...
... A Cornell University study offers further proof that the divergence ... years ago was profoundly influenced by mutations to DNA sequences ... The study, published June 9 in Nature Genetics , ... must play an important role in evolution since there is ...
... June 19, 2013 Elsevier, a world-leading provider of scientific, ... announce the launch of a new open access journal, ... , Elsevier,s earth and planetary science journals portfolio has its ... a forum for rapid publication of top research within the ...
Cached Biology News:New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3
Functionally tested for consistent G-banding of chromosomes....
... optimized for serum-free growth of Ready-Plaque Sf9 ... medium, Sf9 cultures routinely reach densities greater ... above 95%. This medium is also recommended ... staining of pBACgus recombinants develops faster than ...
... is formuatled for the growth of ... Sf21 cells. Grace's Insect Mediu, Unsupplemented ... does not contain lactalbumin hydrosylate, and ... Grace's Insect Medium, Supplemented is formulated ...
TNM-FH Insect Medium 1 liter...
Biology Products: